Serotonin Syndrome and the Combined Use of Deprenyl and An Antidepressant in Parkinson's Disease
Neurol 48:1070-1077, Richard,I.H.,et al, 1997
A Survey of Antidepressant Drug Use in Parkinson's Disease
Neurol 49:1168-1170, Richard,I.H.,et al, 1997
Extrapyramidal Side Effects with Low-Dose Risperidone
Can J Psychiatry 42:325-325, Brown, E.S., 1997
Movement Disorders Associated with the Serotonin Selective Reuptake Inhibitors
J Clin Psychiatry 57:449-454, Leo,R.J., 1996
A Depressed Workman with Heatstroke
Lancet 347:1016, Albukrek,D.,et al, 1996
Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Pts Undergoing Rehab Therapy
Stroke 27:1211-1214, Dam,M.,et al, 1996
Anticonvulsant Effect of Fluoxetine in Humans
Neurol 45:1926-1927, Favale,E.,et al, 1995
Serotonin Syndrome
Neurol 45:219-223, Bodner,R.A.,et al, 1995
The Narcolpetic Syndrome
JNNP 59:221-224, Parkes,J.D.,et al, 1995
Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
J Clin Psychiatry 55:38-45, DeVane,C.L., 1994
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Adult Attention Deficit - Hyperactivity Disorder
NEJM 369:1935-1944, Volkow, N.D. & Swanson, J.M., 2013
Serotonin Syndrome Induced by Transitioning from Phenelzine to Venlafaxine:four Patient Reports
Neurol 51:274-276, Diamond,S.,et al, 1998
The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care
Neurol 45:569-572, Gunderson,C.H., 1995
The Use of Sumatriptan in Patients with Monoamine Oxidase Inhibitors
Neurol 45:1039-1040, Diamond,S., 1995
Newer Concepts in Management of Migraine Headaches
J Med Soc N J 74:11, Haidri,N.H.,et al, 1977
Long-term Therapy of Myoclonus & Other Neurologic Disorders with L-5-Hydroxytryptophan & Carbidopa
NEJM 296:70, VanWoert,M.H.,et al, 1977
Neuropharmacological Aspects of Migraine
Editorial, BMJ 339, 1975, Aug., , 1975
Neuropsychopharmcology & the Affective Disorders
NEJM 281:197, 1969 (three parts) ., Schildkraut,J.J., 1969
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
NEJM 390:1745-1755, 1815, Connolly,S.J.,et al, 2024
Mechanical Thrombectomy in Anticoagulated Patients with Acute Ischemic Stroke, A Meta-Analysis
Neurologist 29:194-203, Zhang,H.L.,et al, 2024
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Advances in Cerebral Venous Thrombosis
Stroke 55:2169-2172, deSousa,D.A. & Neto,L.L., 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
Apixaban vs Aspirin in Patients with Cancer and Cryptogenic Stroke A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial
JAMA Neurol 81:957-965, Navi,B.B.,et al, 2024
Comparative Effects of Drug Interventions for the Acute Management of Migraine Episodes in Adults:Systematic Review and Network Meta-Analysis
BMJ 386:e080107, Karlsson,W.K.,et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke
Neurol 103:e209862, Theodorou,A.,et al, 2024
Optimal Timing of Anticoagulation after Acute Ischaemic Stroke with Atrial Fibrillation (OPTIMAS): A Multicentre, Blinded-Endpoint, Phase 4, Randomised Controlled Trial
Lancet 404:1731-1741, Werring,D.J.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Diagnosis and Management of Cerebral Venous Thrombosis:A Scientific Statement From the American Heart Association
Stroke 55:e77-e90, Saposnik,G.,et al, 2024
Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Perioperative Management of Anticoagulant and Antiplatelet Therapy
NEJM Evid doi:10.1056/EVIDna2200322, Douketis,J.D. & Spyropoulos,A.C., 2023
Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023